The aim of the present study is to observe glycemic control, dose requirements, hypoglycemia
risk, other possible adverse effects and weight changes, as well as to compare these
parameters to prior treatment when patients with type 2 diabetes are initiated and treated
using V-Go during circumstances as close to normal clinical practice as possible.
The main purpose of this study is to evaluate the efficacy and safety of the study drug
known as human regular U-500 insulin (U-500R) administered by continuous subcutaneous
insulin infusion (CSII) versus multiple daily injections (MDI) in participants with type 2
This is an open-label, randomized, forced-titration clinical trial evaluating the efficacy
and safety of Technosphere Insulin (TI) Inhalation Powder in combination with insulin
glargine versus insulin aspart in combination with insulin glargine in subjects with type 2
The purpose of this study is to evaluate the safety and efficacy of BIOD-123 compared to
insulin lispro (Humalog®) when used as part of a basal-bolus regimen in patients with type 1
Evaluate if addition and use of real time continuous glucose monitoring (RT-CGM) improves
glycemic outcome of patients using multiple daily injections (MDI) and self monitoring blood
glucose (SMBG) testing, who are not at target glycemic control.
Patients with type 2 diabetes can attain superior disease outcomes if multiple therapy goals
are simultaneously achieved and maintained. In reality, therapy goals are seldom achieved,
and patients become susceptible to devastating complications and greater health care
expenses. Studies have shown that regular monitoring and therapy adjustments are a
prerequisite to achieving and maintaining therapy goals. Unfortunately implementation of
regular monitoring ... Read More
Like most endocrine axes, the entero-insular axis is expected to go through an age-related
physiological deterioration, what might contribute to special features of the elderly onset
type 2 diabetes in comparison to middle-age.
Twenty four NGT volunteers will be evaluated by a meal tolerance test (MTT) for incretin
hormone measurements, and by the hyperglycemic clamp followed by an arginine test for
assessing the beta-cell function and the acute insulin ... Read More
This is an open label, randomized, parallel group comparison of the immunogenicity safety of
Wockhardt's human insulin and isophane insulin compared with the Novo Nordisk's yeast based
human insulin products (marketed in USA) in type 1 diabetics.
There are two phases of the study, which are as follows:
1. Phase 1 is a comparative phase in which there will be 2 arms (which are described in
the section below).
2. Phase 2 is a follow up phase ... Read More
This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects
on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes.
Patients will be randomized into one of two AC2993 treatment arms or to placebo treatment
and will continue with their required existing diabetes medications (metformin and a
sulfonylurea) throughout the study.
This multicenter, open-label extension study of Protocol 2993-112 is designed to assess
long-term glucose control as measured by HbA1c (glycosylated hemoglobin) and to evaluate
long-term safety and tolerability in subjects treated with metformin who receive
subcutaneously injected AC2993 (10 mcg) administered twice daily. Subjects completing
Protocol 2993-112 are eligible to enroll.
The purpose of this study is to determine the effect of adding liraglutide to high dose
insulin therapy compared to high dose insulin therapy alone in patients with insulin-treated
Type 2 diabetes with insulin requirements of > 100 units of insulin per day.
This is a 24 week study comparing the efficacy of four dose levels of INT131 besylate with
pioglitazone HCl in patients with type 2 diabetes. Eligible patients will be men and women
(of non-childbearing potential or using dual barrier methods of contraception) between 30
and 75 years of age who are minimally responsive to treatment with sulfonylurea monotherapy
or sulfonylurea plus metformin combination therapy.
The purpose of this study is to allow patients with specific needs for inhaled insulin to
continue with inhaled insulin therapy using Technosphere Insulin after Exubera was withdrawn
from the market.
The main purpose of the trial is to evaluate pulmonary function in subjects who had
completed any one of the 4 MKC parent trials (MKC-TI-009, MKC-TI-102, MKC-TI-103, or
MKC-TI-030) for an additional 2-month safety follow-up.
In this placebo controlled study the investigators aim to investigate the effects of vitamin
D supplementation in subjects with new onset of type 1 diabetes on immunological, endocrine
and metabolic parameters.
The purpose of this study is to determine whether excessive secretion of glucagon in type 2
diabetes originates from the pancreatic alpha-cells or endocrine cells in the mucosa of the
To compare glycemic control and treatment satisfaction using a novel bolus insulin patch
(Finesse) versus a pen for initiating and managing bolus insulin dosing in patients with
T2DM not achieving glycemic targets on basal insulin with/without anti-hyperglycemic agents.